Can you take Acetaminophen / pamabrom with Zyrtec?

The cetirizine in Zyrtec has a moderate potential interaction with Acute Alcohol Intoxication.

Alcohol should be avoided when using cetirizine, and some other antihistamines. Cetirizine may produce drowsiness that may be increase by the use of alcohol, sedatives and tranquilizers.

The acetaminophen in acetaminophen / pamabrom has a major potential interaction with Alcoholism.

Chronic alcohol abusers may be at increased risk of hepatotoxicity during treatment with acetaminophen (APAP). Severe liver injury, including cases of acute liver failure resulting in liver transplant and death, has been reported in patients using acetaminophen. Therapy with acetaminophen should be administered cautiously, if at all, in patients who consume three or more alcoholic drinks a day. In general, patients should avoid drinking alcohol while taking acetaminophen-containing medications. Patients should be warned not to exceed the maximum recommended total daily dosage of acetaminophen (4 g/day in adults and children 12 years of age or older), and to read all prescription and over-the-counter medication labels to ensure they are not taking multiple acetaminophen-containing products, or check with a healthcare professional if they are unsure. They should also be advised to seek medical attention if they experience signs and symptoms of liver injury such as fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, and jaundice.

The acetaminophen in acetaminophen / pamabrom has a major potential interaction with Dehydration.

Acetaminophen is contraindicated in patients with severe hepatic impairment or severe active liver disease. Patients with hepatic impairment may be at increased risk of toxicity. Severe liver injury, including cases of acute liver failure and death, have been reported in patients using this drug. Clinical monitoring of hepatic function is recommended. Caution is advised if using acetaminophen in patients with chronic malnutrition or severe hypovolemia. Instruct patients to avoid drinking alcohol while taking acetaminophen-containing medications. Patients should be warned not to exceed the maximum recommended total daily dosage of acetaminophen (4 g/day in adults and children 12 years of age or older), and to read all prescription and over-the-counter medication labels to ensure they are not taking multiple acetaminophen-containing products, or check with a healthcare professional if they are unsure.

The pamabrom in acetaminophen / pamabrom has a moderate potential interaction with Hypokalemia.

The use of pamabrom (a theobromine derivative) has been associated with the renal elimination of potassium due to its diuretic effects. Therapy with pamabrom should be administered cautiously in patients with hypokalemia.

The acetaminophen in acetaminophen / pamabrom has a major potential interaction with Liver Disease.

Acetaminophen is contraindicated in patients with severe hepatic impairment or severe active liver disease. Patients with hepatic impairment may be at increased risk of toxicity. Severe liver injury, including cases of acute liver failure and death, have been reported in patients using this drug. Clinical monitoring of hepatic function is recommended. Caution is advised if using acetaminophen in patients with chronic malnutrition or severe hypovolemia. Instruct patients to avoid drinking alcohol while taking acetaminophen-containing medications. Patients should be warned not to exceed the maximum recommended total daily dosage of acetaminophen (4 g/day in adults and children 12 years of age or older), and to read all prescription and over-the-counter medication labels to ensure they are not taking multiple acetaminophen-containing products, or check with a healthcare professional if they are unsure.

The cetirizine in Zyrtec has a moderate potential interaction with Liver Disease.

Cetirizine is eliminated primarily by the kidney but also undergoes metabolism in the liver to some extent. Patients with renal and/or liver disease may be at greater risk for adverse effects from cetirizine due to decreased drug clearance. The manufacturer recommends an initial dosage of 5 mg once daily in patients 6 years of age and older with decreased renal function (CrCl <= 30 mL/min, including those on hemodialysis) and/or impaired hepatic function. Cetirizine should preferably not be used in children less than 6 years of age with renal and/or hepatic impairment because of the difficulty in reliably administering doses smaller than 2.5 mg (1/2 teaspoonful) and a lack of pharmacokinetic and safety data in this population.

The acetaminophen in acetaminophen / pamabrom has a major potential interaction with Malnourishment.

Acetaminophen is contraindicated in patients with severe hepatic impairment or severe active liver disease. Patients with hepatic impairment may be at increased risk of toxicity. Severe liver injury, including cases of acute liver failure and death, have been reported in patients using this drug. Clinical monitoring of hepatic function is recommended. Caution is advised if using acetaminophen in patients with chronic malnutrition or severe hypovolemia. Instruct patients to avoid drinking alcohol while taking acetaminophen-containing medications. Patients should be warned not to exceed the maximum recommended total daily dosage of acetaminophen (4 g/day in adults and children 12 years of age or older), and to read all prescription and over-the-counter medication labels to ensure they are not taking multiple acetaminophen-containing products, or check with a healthcare professional if they are unsure.

The acetaminophen in acetaminophen / pamabrom has a moderate potential interaction with Phenylketonuria.

Several oral acetaminophen and acetaminophen-combination products, particularly flavored chewable tablets, contain the artificial sweetener, aspartame (NutraSweet). Aspartame is converted to phenylalanine in the gastrointestinal tract following ingestion. Chewable and effervescent formulations of acetaminophen products may also contain phenylalanine. The aspartame/phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e. phenylketonurics).

The cetirizine in Zyrtec has a moderate potential interaction with Renal Dysfunction.

Cetirizine is eliminated primarily by the kidney but also undergoes metabolism in the liver to some extent. Patients with renal and/or liver disease may be at greater risk for adverse effects from cetirizine due to decreased drug clearance. The manufacturer recommends an initial dosage of 5 mg once daily in patients 6 years of age and older with decreased renal function (CrCl <= 30 mL/min, including those on hemodialysis) and/or impaired hepatic function. Cetirizine should preferably not be used in children less than 6 years of age with renal and/or hepatic impairment because of the difficulty in reliably administering doses smaller than 2.5 mg (1/2 teaspoonful) and a lack of pharmacokinetic and safety data in this population.